The following stocks had notable activity in their options during the past week: $HOLX (5/7/13): 3,900 DEC 22.0/18.0 strike Strangles were purchased for a net debit of 2.05 or a total cost of $799,500. DEC 22.0 Calls were bought for 1.00 and DEC 18.0 strike Puts were bought for 1.05 (stock at $20.66). Buyer makes […]
Preview of ASCO2013 Take One
With the 2013 annual meeting of the American Society of Clinical Oncology (ASCO) rapidly approaching, we want to take the time to present our highlights of the meeting. This is one of the largest medical meetings investors focus upon in the biotech and healthcare sectors. Before we get into this, we do have some overarching […]
Notes from JP Morgan Healthcare Conference (Monday/Tuesday session)
As we go into the 3rd day of the JP Morgan Healthcare Conference, we wanted to provide some highlights and notes from the first 2 sessions. I tried to keep them as concise as possible. Day 1 Clearly, Celgene Corp.(NASDAQ: CELG) came firing out of the gates by announcing strong financial guidance. This included in-line […]
2012 ASH Meeting – Myelofibrosis, Lymphoma, Myeloma
It’s going to be a busy few days at ASH, which begins December 8 in Atlanta. A huge amount of data will be presented; here is an overview of some interesting abstracts. YMI: YM Biosciences Title: Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis YM Biosciences will present final safety […]
What we’re looking for at ASH 2012
On Monday, November 5th, abstracts submitted to 2012 Annual Meeting of the American Society of Hematology (ASH) Annual Meeting will be published online. A time has not been released, but we have heard they will be released at 10AM Eastern time. Below are some comments on companies we expect to have a present at the […]
SGEN – Update on Seattle Genetics
A series of recent moves by Seattle Genetics is positioning the company to capitalize on its current success to build for future growth. As previously mentioned in our last report, Seattle Genetics is on track to start three Phase III studies for Adcetris in the front line setting this year: Hodgkin’s Lymphoma (HL), Mature T-cell […]
SGEN – 2011 Q4 Report: Adcetris Launch On Track
SGEN 2011 Q4 Report: Adcetris Launch On Track 2/13/2012 Well, that certainly didn’t seem to go well. On a day when Regeneron (NASDAQ:REGN) saw its stock jump 12% on better than expected sales guidance of its macular degeneration treatment Eylea, Seattle Genetics (NASDAQ:SGEN) stock tumbled 5% the next day for only meeting quarterly revenue estimates. […]
ASH Stock Preview
2011 ASH Stock Preview It’s the end of the year, which can mean only one thing- the American Society of Hematology Convention is coming up! ASH is the year’s largest meeting for researchers and investors interested in hematology, or blood cancers. This year’s convention will be held from December 9th through 12th in sunny San […]
Antibody Engineering Wars
Therapeutic antibodies have been in use for decades now, becoming a mainstay for the treatment of cancer and inflammatory diseases. The molecules have evolved quickly through scientific advancements from simple mouse antibodies to complex humanized antibody-drug conjugates. Rapid growth in this category has grabbed Big Pharma’s attention, shifting its focus away from traditional small molecule […]
Seattle Genetics Consolidating Its Strong ADC Position
Today, Seattle Genetics announced a partnership with Abbott to develop a drug against a single target using their antibody-drug-conjugate (ADC) technology. Abbott will pay $8 million upfront and up to $200 million in milestones as well as royalties on worldwide sales, if any. This deal comes quickly after news of the expansion of an ADC […]
Seattle Genetics and Immunogen: Fabless Biotechs?
Jason Chew The results are in and it appears Seattle Genetics’ Antibody Drug Conjugate (ADC) technology does indeed work after all- not that it should be a surprise to anyone following the company. Results released early Monday morning showed 75% of relapsed or refractory Hodgkin’s Lymphoma (HL) patients taking the drug Brentuximab Vendotin, or as […]
Next Generation Antibody Technologies- Seattle Genetics Leads the Way
Next Generation Antibody Technologies- Seattle Genetics Leads the Way Monoclonal Antibody Technology has revolutionized medicine. Since 1986, more than 20 Antibody drugs have been approved, with sales of $26 Billion in 2007 and expected to nearly double to $49 Billion by 2013. Sales are highly concentrated, with the top five drugs- Avastin, Rituxin Herceptin, Humira, […]
